Project Grant R01HL173606
Award Date
7/20/25
Completion Date
4/30/30
Dollars Obligated
$829K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $685,884 to the University of North Carolina at Chapel Hill to conduct research on the regulation of coagulation and thrombosis by C1 inhibitor. The research aims to elucidate the molecular mechanisms by which endogenous C1 inhibitor regulates coagulation and venous thrombosis, evaluate the impact of C1 inhibitor deficiency on coagulation...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $172,800 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on July 20, 2025, will fund research to predict the hemodynamic response to mitral valve interventions using pressure-volume analysis. The research aims to: 1) identify new echocardiographic measures of left ventricular systolic function in...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $130,337 to The Trustees of Columbia University in the City of New York, Health Sciences Division, to conduct research on understanding the regulation and role of extramedullary hematopoiesis (the formation of blood cells outside the bone marrow) in the liver. The key objectives are to: 1) characterize the cellular components of the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on enabling clinicians to better leverage information from carotid computed tomographic angiography (CTA) scans to assess stroke risk. The $771,485 award, effective August 1, 2025 through May 31, 2030, aims to: 1) identify reliable imaging-derived carotid plaque features associated with cryptogenic stroke, 2) develop an advanced...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $500,660 to The Trustees of Columbia University in the City of New York, from Aug 1, 2025 to May 31, 2029. The grant aims to advance statistical methods for pooling data from multiple longitudinal cohort studies, in order to improve the robustness and generalizability of findings from such studies. Specifically, the project will develop...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $764,817 to the University of North Carolina at Chapel Hill to conduct research on the mechanisms of coagulopathy and bleeding in acute promyelocytic leukemia (APL). The study aims to determine the individual contributions of the podoplanin-CLEC-2 pathway, the S100/Annexin A2/tissue plasminogen activator and the urokinase-type plasminogen...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $792,498 to the Trustees of Indiana University, Indianapolis (IU Indianapolis) to conduct research on hematopoietic stem cells (HSCs) and their regulation under low oxygen tension (hypoxia). The primary goals are to: 1) understand how hypoxia activates the transcription factor TFE3 to facilitate HSC self-renewal, 2) determine...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,922 to the Albert Einstein College of Medicine to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis. The research will utilize zebrafish models and human induced pluripotent stem cells (iPSCs) to characterize changes in hematopoietic stem and progenitor cells, as well as differentiated progeny, under these...
This National Science Foundation (NSF) Engineering program (CFDA 47.041) project grant award of $650,000 to The Trustees of Columbia University in the City of New York will support research to advance understanding of the blood-clot interactions that may result in stroke for patients with heart rhythm disorders like atrial fibrillation. The research aims to create a computational model of the left atrium to investigate how the heart's structure changes blood flow patterns, elevating the risk...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $420,600 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Colorado-Denver. The grant's objective is to design elastic hydrogel microparticles as a platform to measure key elements of platelet function, including adhesion, activation, aggregation, and contraction. This innovative "lab-on-a-particle" approach aims to improve the reliability and reproducibility of platelet function...